Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252536 · ClinicalTrials.gov registry record · Phase 2
HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 2
- Development phase
- 346
- Enrollment target
- 10
- Study locations
NCT02252536: Completed Phase 2 study of Alcohol Use Disorder, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
NCT02252536 is a Phase 2 study of Alcohol Use Disorder that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 346 participants, roughly in line with the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target. The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02252536, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 346 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.
Primary Outcome
The primary objective of the study is to compare the efficacy of HORIZANT (gabapentin enacarbil) Extended-Release Tablets 600 mg twice daily (BID) with matched placebo on the primary alcohol consumption outcome endpoint, percentage of subjects with no heavy drinking days (PSNHDD) during the last 4 weeks of treatment, among patients with Alcohol Use Disorder (AUD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG gabapentin enacarbil
Study Locations (10)
California
- University of California Los Angeles - Los Angeles
- Friends Research Institute - San Francisco
Florida
- University of Miami, Miller School of Medicine - Miami
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Massachusetts
- Boston University Medical Center - Boston
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
New York
- Mount Sinai St. Luke's Hospital - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
What the finished NCT02252536 record still lists
NCT02252536 is an interventional study that assigns participants to a tested intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02252536 lists 10 locations in 9 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT02252536 about?
NCT02252536 is a clinical study titled "HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder". The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.
What is the current status of trial NCT02252536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 346 participants. The study started on 2015-06. Estimated completion is 2017-03.
What conditions does trial NCT02252536 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT02252536?
The interventions under investigation include: Placebo (DRUG), gabapentin enacarbil (DRUG).
Who is sponsoring clinical trial NCT02252536?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02252536 being conducted?
This trial has 10 study locations across California, Florida, Maryland, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02252536's enrollment target sits among peer trials
346 26th of 184 higher than 159 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia